What clinical trials has Neurocept registered on ClinicalTrials.gov and what are their start/completion dates?

1. Why the NCT06769659 listing matters — a single clear registration with mixed completion dates

ClinicalTrials.gov identifier NCT06769659 appears consistently across the analyses as a trial evaluating NPT 2042 versus placebo in subjects aged 16–75 with genetic generalized epilepsy and absence seizures; the trial’s listed start date is March 11, 2025, a fact repeated in two independent summaries. The analyses diverge on the study’s projected completion window: one summary estimates a May 30, 2026 completion, while another lists March 30, 2026 with results due by March 30, 2027. These conflicting completion dates indicate either updates to the registry after initial posting or inconsistent reporting between sources; the consistent start date and trial focus are the strongest common facts. ^{[1] [2]}

2. What each analysis claims — aligning concordant facts and flagging contradictions

One analysis presents the study as active and recruiting with an estimated completion of May 30, 2026, while another presents the same NCT number but lists an earlier completion estimate of March 30, 2026 and a formal results reporting deadline of March 30, 2027. Both analyses agree on the start date of March 11, 2025 and identify the sponsor name as NeuroPro Therapeutics, Inc., which appears to be used interchangeably with Neurocept in the presented material. The presence of two different completion dates is the primary factual conflict; either the registry’s estimated completion date changed over time or the two summaries captured different registry snapshots. ^{[1] [2]}

3. Broader claims about other Neurocept trials — sparse evidence and possible conflation

A separate analysis claims Neurocept registered multiple trials historically — naming studies such as KINECT-HD2, NBI-98854-DCP3018, NBI-1076986, and NBI-921355 — but does not provide verifiable start or completion dates in the provided excerpt. Those trial names align with studies in movement disorders and epilepsy historically associated with other sponsors or partnered organizations, so the claim that Neurocept itself registered all those trials lacks direct corroboration in the supplied analyses. The absence of specific ClinicalTrials.gov identifiers or dates in that analysis leaves the multiple-trial assertion unverified based on the available data. ^[3]

4. Naming and sponsorship confusion — Neurocept versus NeuroPro Therapeutics

The analyses show potential naming ambiguity, with the sponsor listed as NeuroPro Therapeutics, Inc. in some summaries while the user’s original query references Neurocept. This suggests either a corporate rebranding, an affiliated subsidiary relationship, or a reporting inconsistency in secondary summaries. The single clearly identified ClinicalTrials.gov record (NCT06769659) is associated with the NeuroPro name in one analysis and attributed to Neurocept in another, so the association between the corporate names and the trial registry entry remains plausible but not definitively established from the provided material. Clarifying corporate identity on the official registry entry would resolve this. ^{[1] [2] [3]}

5. What remains uncertain and the practical next steps for verification

Key unresolved facts are the exact estimated completion date for NCT06769659 and whether Neurocept/NeuroPro has additional active or completed registrations. The most reliable way to resolve these is to view the live ClinicalTrials.gov record for NCT06769659 and search the registry for both corporate names and the specific investigational product NPT 2042. Based on the supplied analyses, the strongest, verifiable claim is that NCT06769659 began on March 11, 2025 and targets genetic generalized epilepsy; other completion dates and the broader set of trials remain uncorroborated in the provided material. ^{[1] [2] [3]}